# Allergy Therapeutics appoints Cheryl MacDiarmid to Board of Directors

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-appoints-cheryl-macdiarmid-to-board-of-directors/4121029987
- Published: 2021-10-27T07:12:12+01:00
- Author: Giles

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated specialty pharmaceutical group specialising in allergy vaccines,
has announced the appointment of Cheryl MacDiarmid as a Non-Executive Director of
the Company, with effect from 27 October 2021. Upon appointment Cheryl will also
become a member of the Audit Committee.   

Cheryl has more than 25 years’ experience in commercial roles within the global 
pharmaceuticals sector. She brings significant marketing, strategy and management
expertise, having worked for [GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)(
GSK) since 1993, where she has focussed mainly on the commercial aspects of the 
business, developing a deep knowledge of sales and marketing operations in North
America. Cheryl has significant senior management experience within GSK, initially
in Canada and then in the US where she led the Respiratory Business Unit and associated
US operations. In 2019 Cheryl was appointed Senior Vice President and Head, Global
Commercial Strategy for ViiV Healthcare, the joint venture between GSK, Pfizer and
Shionogi which specialises in the development of therapies for HIV.    

> **Peter Jensen, Chairman of Allergy Therapeutics, commented: **“We are delighted
> to welcome Cheryl to the Board of Allergy Therapeutics. Cheryl brings highly relevant
> experience, with her knowledge of the healthcare sector, expertise in marketing
> and commercial strategy, and her understanding of the US market, especially in
> the light of our recent announcement that our pivotal G306 Phase III trial is 
> on track to commence in H2 2022 in US and Europe. I have no doubt she will be 
> an important contributor to the Board.”

> **Commenting on her appointment, Cheryl MacDiarmid said: **“I am delighted to 
> be joining the Board of Allergy Therapeutics at an exciting time for the Company.
> I look forward to helping the Board to further strengthen Allergy’s leadership
> in the allergy immunotherapeutics field, providing innovative products to help
> people worldwide.”

**Additional Disclosures**

The following information is disclosed pursuant to Schedule Two paragraph (g) of
the AIM Rules of Companies.

Ms Cheryl Faye MacDiarmid (aged 53) holds or has held the following current and 
former directorships in the past five years:

| Current Directorships | Former Directorships in the past five years | 
| PHIVCO UK Limited | ViiV Healthcare Finance 1 Limited | 
| PHIVCO UK II Limited |  | 
| ViiV Healthcare Finance Limited |  | 
| ViiV Healthcare Overseas Limited |  | 
| ViiV Healthcare UK Limited |  | 
| ViiV Healthcare Trading Services UK Limited |  | 
| ViiV Healthcare UK (No.3) Limited |  | 
| ViiV Healthcare UK (No.4) Limited |  | 
| ViiV Healthcare UK (No.5) Limited |  | 
| ViiV Healthcare UK (No.6) Limited |  | 
| ViiV Healthcare UK (No.7) Limited |  |

Save as set out above, no further information regarding Cheryl MacDiarmid is required
to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.

Share on:
